Aurobindo Pharma Limited is a pharmaceutical company established in 1986 by Mr. P.V. Ramaprasad Reddy with other highly committed professionals.
The company has its headquarters in Hyderabad in India and Aurobindo Pharma started its operations in 1988 with a single unit which manufactured SSP (Semi-Synthetic Penicillin) at Pondicherry. Aurobindo Pharma is present in therapeutic areas like Cardiovascular, Anti-diabetics, Gastroenterology and Neurosciences among others.
The company also entered the specialty Generics segment for high margins through its effective production capabilities and it is also into manufacturing APIs and Formulation products.
The company has dedicated R&D facilities that discovers new drugs and formulations. This year it invested approximately 400 crores.
Aurobindo Pharma has global presence exporting its products to around 125 countries and over 70 percent of revenue from international operations. It has multiple facilities which are approved by leading regulatory agencies.
The core strengths of Aurobindo Pharma are:
Scales and Leadership- because of its large manufacturing and R&D facilities as well as its well diversified portfolio.
Operational Excellence- because of technology and know-how for specialty formulations.
Service Delivery- because of its global marketing network and customer centric approach.
In 2014 Aurobindo Pharma acquired generic operations of Pharma Company named Actavis in seven western countries.
Aurobindo Pharma is actively involved in CSR activities by providing subsidized transport to local people and held medical camps for employees as well as their families. The marketing partners of Aurobindo includes Pfizer and AstraZeneca.